Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. L&C Bio Co., Ltd
  6. Summary
    A290650   KR7290650001

L&C BIO CO., LTD

(A290650)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
34700 33300 33400 33900 34900 Last
88364 159747 72180 112783 811524 Volume
0.00% -4.03% +0.30% +1.50% +2.95% Change
Estimated financial data (e)
Sales 2019 29 152 M 25,3 M 25,3 M
Net income 2019 7 250 M 6,30 M 6,30 M
Net cash position 2019 27 121 M 23,6 M 23,6 M
P/E ratio 2019 25,9x
Yield 2019 -
Sales 2020 32 973 M 28,7 M 28,7 M
Net income 2020 10 813 M 9,40 M 9,40 M
Net cash position 2020 12 311 M 10,7 M 10,7 M
P/E ratio 2020 69,9x
Yield 2020 0,14%
Capitalization 792 B 688 M 688 M
EV / Sales 2019 5,53x
EV / Sales 2020 22,5x
Nbr of Employees 74
Free-Float 66,1%
More Financials
Company
L&C BIO Co., Ltd is a Korea-based Company mainly engaged in the regenerative medicine business. The Company mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The Company also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others. 
More about the company
All news about L&C BIO CO., LTD
2020NETMARBLE : Skin care kiosk developer lululab secures funding
AQ
2020Tranche Update on L&C BIO Co., LTD's Equity Buyback Plan announced on June 15..
CI
2020L&C BIO Co., LTD's Equity Buyback announced on June 15, 2020, has closed with..
CI
2020L&C BIO Co., LTD announces an Equity Buyback for 91,996 shares.
CI
2020L&C BIO Co., Ltd authorizes a Buyback Plan.
CI
2020L&C BIO Co., Ltd announced that it has received KRW 10 billion in funding fro..
CI
2020L&C BIO Co., Ltd announced that it expects to receive KRW 10 billion in fundi..
CI
2019Gene Medicine Co., Ltd. announced that it has received KRW 476.475 million in..
CI
2019Gene Medicine Co., Ltd. announced that it expects to receive KRW 476.475 mill..
CI
2019L & C BIO CO.,LTD.(KOSE : A290650) added to S&P Global BMI Index
CI
2018L & C BIO Co.,Ltd. has completed an IPO in the amount of KRW 24 billion.
CI
2018L & C BIO Co.,Ltd. has filed an IPO.
CI
More news
News in other languages on L&C BIO CO., LTD

- No features available -

More news
Chart L&C BIO CO., LTD
Duration : Period :
L&C Bio Co., Ltd Technical Analysis Chart | A290650 | KR7290650001 | MarketScreener
Technical analysis trends L&C BIO CO., LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Last Close Price 34 900,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Hwan-Chul Lee Chief Executive Officer & Director
Hae-Seok Hwang Independent Director
Hyung-Gu Kim Director & Vice President
Jong-Oh Choi Auditor
Sector and Competitors